Free Trial

Q2 Earnings Forecast for RAPT Issued By Lifesci Capital

Rapt Therapeutics logo with Medical background

Rapt Therapeutics (NASDAQ:RAPT - Free Report) - Research analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for Rapt Therapeutics in a research report issued on Tuesday, July 22nd. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings per share of ($0.67) for the quarter. Lifesci Capital currently has a "Strong-Buy" rating and a $31.00 price target on the stock. The consensus estimate for Rapt Therapeutics' current full-year earnings is ($2.14) per share. Lifesci Capital also issued estimates for Rapt Therapeutics' Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.59) EPS.

Other analysts have also issued reports about the stock. Wall Street Zen lowered shares of Rapt Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 21st. UBS Group lowered their price objective on shares of Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Finally, HC Wainwright raised their price objective on shares of Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a report on Thursday, July 10th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $21.67.

Check Out Our Latest Analysis on RAPT

Rapt Therapeutics Stock Performance

Shares of NASDAQ RAPT traded up $0.66 during trading hours on Friday, hitting $13.31. The company's stock had a trading volume of 66,312 shares, compared to its average volume of 130,058. The stock has a market cap of $220.15 million, a price-to-earnings ratio of -0.69 and a beta of -0.09. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $27.84. The business has a 50-day simple moving average of $8.88 and a 200-day simple moving average of $8.74.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.48) by $1.84.

Hedge Funds Weigh In On Rapt Therapeutics

Several large investors have recently made changes to their positions in the business. Simplicity Wealth LLC purchased a new position in Rapt Therapeutics in the 1st quarter worth approximately $25,000. Exchange Traded Concepts LLC raised its holdings in Rapt Therapeutics by 27.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 113,738 shares of the company's stock worth $139,000 after acquiring an additional 24,662 shares during the last quarter. Callan Family Office LLC raised its holdings in Rapt Therapeutics by 53.9% in the 1st quarter. Callan Family Office LLC now owns 89,327 shares of the company's stock worth $109,000 after acquiring an additional 31,287 shares during the last quarter. Comerica Bank raised its holdings in Rapt Therapeutics by 53.9% in the 1st quarter. Comerica Bank now owns 89,327 shares of the company's stock worth $109,000 after acquiring an additional 31,287 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Rapt Therapeutics by 4.9% in the 4th quarter. Geode Capital Management LLC now owns 716,937 shares of the company's stock worth $1,133,000 after acquiring an additional 33,758 shares during the last quarter. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

About Rapt Therapeutics

(Get Free Report)

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Featured Articles

Earnings History and Estimates for Rapt Therapeutics (NASDAQ:RAPT)

Should You Invest $1,000 in Rapt Therapeutics Right Now?

Before you consider Rapt Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.

While Rapt Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines